ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
CTLA4 억제제 시장 규모는 향후 수년간 급성장이 전망될 예정입니다. 연구개발 투자 증가, 새로운 치료 적응증의 연구 확대 등에 기인한다고 생각됩니다. 예측 기간 중에 예상되는 주요 동향으로는 면역요법의 발전, 단일클론항체의 도입, 차세대 CTLA4 억제제의 개발, 맞춤형 의료의 대두, 암 면역 요법의 지속적인 진보 등을 들 수 있습니다.
암의 유병률 증가는 향후 수년간 CTLA4 억제제 시장 확대를 촉진할 것으로 예측됩니다. 암 이환율 증가의 배후에 있는 중요한 요인은 발암물질에 장기간에 걸친 노출이며, 이는 세포의 악성화를 초래하는 유전자 변이를 직접 유발합니다. 예를 들어, 2024년 2월 스위스에 본부를 둔 글로벌 공중 보건 기관인 세계보건기구는 2022년에 약 2천만 건의 새로운 암 사례가 발생했으며, 이로 인해 약 1천만 명이 사망했다고 보고했습니다. 2050년에는 연간 암 발생 건수가 2022년 대비 77% 증가한 3,500만 건에 달할 것이라는 예측도 있습니다. 그 결과, 암 이환율의 상승이 CTLA4 억제제 시장 성장에 기여하고 있습니다.
CTLA4 억제제 시장의 주요 기업은 암에 대한 면역계의 반응을 강화하고 진행암과 치료저항성 암 환자의 예후를 개선하기 위한 병용치료를 진행함으로써 면역요법의 혁신을 진행하고 있습니다. 그리고 단독요법보다 효과적으로 암세포에 대한 면역활성을 높이고 CTLA4 억제제의 효과를 증폭시키는 것입니다. 예를 들어, 2025년 2월, 중국에 본사를 둔 생명공학 회사인 이노벤트 바이오로직스는 이필리무맙 주사제에 대한 신약 허가 신청(NDA)이 중국 국가약품감독관리국(NMPA)의 의약품평가센터(CDE)에서 승인되어 우선 심사 지위를 부여받았다고 발표했습니다. 회복 결손(dMMR) 대장암에 대한 네오애쥬번트 치료로서, 신틸리맙과의 병용에 관한 것입니다. 이것은 중국 국내에서 개발된 최초의 CTLA4 억제제이며, 혁신적인 암 치료에 있어서의 중국의 진보를 부각하는 것입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 CTLA4 억제제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 CTLA4 억제제 시장 : 성장률 분석
세계의 CTLA4 억제제 시장 실적 : 규모와 성장(2019-2024년)
세계의 CTLA4 억제제 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 CTLA4 억제제 전체 시장(TAM)
제6장 시장 세분화
세계의 CTLA4 억제제 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
단독 요법
병용 요법
세계의 CTLA4 억제제 시장 : 작용 기전별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
표적 억제
면역 체크포인트 억제
공동 자극 부스팅
세계의 CTLA4 억제제 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
정맥(IV)
경구
피하
세계의 CTLA4 억제제 시장 : 적응증별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
흑색종
비소세포폐암(NSCLC)
대장암
기타 악성 종양
세계의 CTLA4 억제제 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
전문 클리닉
연구기관
재택 헬스케어
세계의 CTLA4 억제제 시장 : 단독 요법 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
1차 치료
2차 치료
구제 요법
세계의 CTLA4 억제제 시장 : 병용 요법 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
CTLA4 억제제와 PD-1/PD-L1 억제제
CTLA4 억제제와 화학치료
CTLA4 억제제와 표적치료
CTLA4 억제제와 방사선치료
CTLA4 억제제와 기타 면역치료
제7장 지역별/국가별 분석
세계의 CTLA4 억제제 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 CTLA4 억제제 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
CTLA4 억제제 시장 : 경쟁 구도
CTLA4 억제제 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol-Myers Squibb Company : 개요, 제품 및 서비스, 전략 및 재무 분석
AstraZeneca plc : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Eli Lilly and Company
Amgen Inc.
BioNTech SE
Regeneron Pharmaceuticals Inc.
Incyte Corporation
BeiGene Ltd.
Innovent Biologics Inc.
MacroGenics Inc.
Akeso Inc.
Agenus Inc.
Harbour BioMed
NextCure Inc.
Xilio Therapeutics Inc.
Shattuck Labs Inc.
CytomX Therapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
CTLA4 억제제 시장(2029년) : 새로운 기회를 제공하는 국가
CTLA4 억제제 시장(2029년) : 새로운 기회를 제공하는 부문
CTLA4 억제제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
KTH
영문 목차
영문목차
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors are a class of immunotherapy agents that block the CTLA-4 receptor on T cells, thereby enhancing immune activation and promoting anti-tumor responses. By preventing the inhibitory signals that suppress T cell proliferation and function, these inhibitors boost the immune system's ability to target and destroy cancer cells. They are primarily used in oncology to treat cancers such as melanoma and non-small cell lung cancer (NSCLC), and are also being explored for their potential in managing autoimmune diseases and transplant rejection.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main types of CTLA-4 inhibitors include monotherapy and combination therapy. Monotherapy CTLA-4 inhibitors are used alone, without other treatments, to activate T cells and enhance the immune response against tumors. Their mechanisms of action involve targeted inhibition, immune checkpoint blockade, and co-stimulatory enhancement. These therapies are administered via intravenous (IV), oral, or subcutaneous routes for indications including melanoma, NSCLC, colorectal cancer, and others. Key end users include hospitals, specialty clinics, research institutions, and home healthcare settings.
The CTLA4 inhibitors market research report is one of a series of new reports from The Business Research Company that provides CTLA4 inhibitors market statistics, including CTLA4 inhibitors industry global market size, regional shares, competitors with a CTLA4 inhibitors market share, detailed CTLA4 inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the CTLA4 inhibitors industry. This CTLA4 inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The CTLA4 inhibitors market size has grown rapidly in recent years. It will grow from$4.87 billion in 2024 to $5.68 billion in 2025 at a compound annual growth rate (CAGR) of 16.7%. The growth during the historic period can be attributed to the rising incidence of cancer, an increasing emphasis on immuno-oncology, greater funding and investment in cancer immunotherapy research, the expanding use of immunotherapy treatments, and the growing number of studies focused on combination therapies.
The CTLA4 inhibitors market size is expected to see rapid growth in the next few years. It will grow to$10.47 billion in 2029 at a compound annual growth rate (CAGR) of 16.5%. The growth during the forecast period can be attributed to the increasing demand for immune checkpoint inhibitors, a growing aging population, heightened awareness of early cancer detection, rising investments in research and development, and the expansion of research into new therapeutic indications. Key trends expected in the forecast period include advancements in immunotherapy, the introduction of monoclonal antibodies, the development of next-generation CTLA-4 inhibitors, the rise of personalized medicine, and continued progress in cancer immunotherapy.
The increasing prevalence of cancer is anticipated to drive the expansion of the CTLA-4 inhibitors market in the coming years. Cancer is a multifaceted group of diseases characterized by the uncontrolled proliferation and spread of abnormal cells, which can infiltrate nearby tissues and interfere with normal bodily functions. A key factor behind the growing incidence of cancer is prolonged exposure to carcinogens, which directly induces genetic mutations that result in the malignant transformation of cells. Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) inhibitors help address the rising cancer burden by boosting the immune system's capacity to detect and destroy cancer cells, thereby enhancing treatment effectiveness and providing new options for patients with advanced or resistant cancers. For example, in February 2024, the World Health Organization, a Switzerland-based global public health agency, reported that nearly 20 million new cancer cases occurred in 2022, leading to around 10 million deaths. Projections indicate that annual cancer cases could reach 35 million by 2050, representing a 77% rise from 2022 levels. As a result, the rising incidence of cancer is contributing to the growth of the CTLA-4 inhibitors market.
Key players in the CTLA-4 inhibitors market are innovating in immunotherapy by advancing combination treatments to strengthen the immune system's response to cancer and enhance outcomes for patients with advanced or treatment-resistant forms of the disease. Combination therapy involves the simultaneous use of two or more treatments, which amplifies the impact of CTLA-4 inhibitors by enhancing immune activity against cancer cells more effectively than monotherapy. For instance, in February 2025, Innovent Biologics Inc., a biotechnology company based in China, announced that the New Drug Application (NDA) for its ipilimumab injection had been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) and granted Priority Review status. This application concerns its use in combination with sintilimab as a neoadjuvant treatment for resectable microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colon cancer. This marks the first CTLA-4 inhibitor developed domestically in China, highlighting the nation's progress in innovative cancer therapies.
In March 2023, BioNTech SE, a biotechnology company headquartered in Germany, entered into a collaboration with OncoC4, Inc. to advance the field of cancer immunotherapy by improving the effectiveness and safety profile of immune checkpoint inhibitors. This partnership aims to co-develop and commercialize ONC-392, OncoC4's next-generation anti-CTLA-4 monoclonal antibody candidate, both as a standalone treatment and in combination with anti-Programmed Cell Death Protein 1 (PD-1) therapies. The goal is to improve outcomes across various solid tumor types by leveraging BioNTech's oncology capabilities and proprietary development pipeline. OncoC4 Inc., based in the United States, specializes in pioneering cancer immunotherapy solutions, including CTLA-4 antibodies.
Major players in the ctla4 inhibitors market are Pfizer Inc., Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., BioNTech SE, Regeneron Pharmaceuticals Inc., Incyte Corporation, BeiGene Ltd., Innovent Biologics Inc., MacroGenics Inc., Akeso Inc., Agenus Inc., Harbour BioMed, NextCure Inc., Xilio Therapeutics Inc., Shattuck Labs Inc., CytomX Therapeutics Inc.
North America was the largest region in the CTLA4 inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in CTLA4 inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the CTLA4 Inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The CTLA4 inhibitors market consists of sales of monoclonal antibodies, biologics, biosimilars, and checkpoint inhibitor-based immunotherapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
CTLA4 Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on ctla4 inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for ctla4 inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ctla4 inhibitors market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Monotherapy; Combination Therapy
2) By Mechanism Of Action: Targeted Inhibition; Immune Checkpoint Blockade; Co-Stimulatory Boosting
3) By Route Of Administration: Intravenous (IV); Oral; Subcutaneous
4) By Indication: Melanoma; Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer; Other Malignancies
5) By End User: Hospitals; Specialty Clinics; Research Institutions; Home Healthcare Settings
Subsegments:
1) By Monotherapy: First-Line Treatment; Second-Line Treatment; Salvage Therapy
2) By Combination Therapy Subsegments: CTLA-4 Inhibitors With PD-1/PD-L1 Inhibitors; CTLA-4 Inhibitors With Chemotherapy; CTLA-4 Inhibitors With Targeted Therapy; CTLA-4 Inhibitors With Radiotherapy; CTLA-4 Inhibitors With Other Immunotherapies
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. CTLA4 Inhibitors Market Characteristics
3. CTLA4 Inhibitors Market Trends And Strategies
4. CTLA4 Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global CTLA4 Inhibitors Growth Analysis And Strategic Analysis Framework
5.1. Global CTLA4 Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global CTLA4 Inhibitors Market Growth Rate Analysis
5.4. Global CTLA4 Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global CTLA4 Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global CTLA4 Inhibitors Total Addressable Market (TAM)
6. CTLA4 Inhibitors Market Segmentation
6.1. Global CTLA4 Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monotherapy
Combination Therapy
6.2. Global CTLA4 Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Targeted Inhibition
Immune Checkpoint Blockade
Co-Stimulatory Boosting
6.3. Global CTLA4 Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous (IV)
Oral
Subcutaneous
6.4. Global CTLA4 Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Melanoma
Non-Small Cell Lung Cancer (NSCLC)
Colorectal Cancer
Other Malignancies
6.5. Global CTLA4 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Research Institutions
Home Healthcare Settings
6.6. Global CTLA4 Inhibitors Market, Sub-Segmentation Of Monotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
First-Line Treatment
Second-Line Treatment
Salvage Therapy
6.7. Global CTLA4 Inhibitors Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
CTLA-4 Inhibitors With PD-1/PD-L1 Inhibitors
CTLA-4 Inhibitors With Chemotherapy
CTLA-4 Inhibitors With Targeted Therapy
CTLA-4 Inhibitors With Radiotherapy
CTLA-4 Inhibitors With Other Immunotherapies
7. CTLA4 Inhibitors Market Regional And Country Analysis
7.1. Global CTLA4 Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global CTLA4 Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
